We offer the latest in technology and minimally invasive techniques to treat endocrine conditions.

Thyroid Cancer Treatments

Laparoscopic Adrenalectomy: Laparoscopic adrenalectomy is most commonly performed to remove tumors from the adrenal gland, which is responsible for producing hormones.

Minimally Invasive Parathyroidectomy (MIP): Minimally invasive parathyroidectomy (MIP) consists of identifying a single abnormal gland and removing it without the identification of the remaining normal parathyroid glands.

Parathyroid Surgery: Parathyroid surgery involves identifying all four parathyroid glands but removing only those that are abnormal.

Radioactive Iodine: Thyroid cancer patients with papillary or follicular thyroid cancer often receive a dose of radioactive iodine approximately four to six weeks after their surgery in an attempt to destroy (ablate) any remaining thyroid cells in their bodies.

Thyroid Cancer Research

Our team conducts many types of research aimed at improving the care of our patients. The results of this research are readily translated into best practices at UW Health, which benefits our patients and referring providers.

Our team runs a laboratory that is developing novel therapeutics for thyroid cancer and neuroendocrine tumors. Among our current research initiatives are efforts to investigate the development, progression and treatment of endocrine tumors, including medullary thyroid cancer, gastrointestinal carcinoids, differentiated thyroid cancer, adrenal cancer and pancreatic islet cell tumors.

Our robust clinical research program is helping to establish standard of care for patients with endocrine diseases. We conduct extensive research focused on patient-centered outcomes and symptom resolution and are helping to optimize the surgical care of endocrine disease. The results of this type of research are quickly brought into clinical practice showcasing our bench to bedside mission. We utilize population-level data to discover trends in disease presentation and treatment as well as participate in multi-institutional studies that have impacted treatment guidelines.

We have a variety of clinical trials available for the treatment of neuroendocrine tumors, treatment-resistant thyroid cancer and medullary thyroid cancer.